Mesoblast Limited (ASX:MSB)
Australia · Delayed Price · Currency is AUD 2.420
+0.070 (2.98%)
Feb 26, 2026, 2:19 PM AEST
Mesoblast Employees
Mesoblast had 81 employees as of June 30, 2025. The number of employees increased by 8 or 10.96% compared to the previous year.
Employees
81
Change (1Y)
8
Growth (1Y)
10.96%
Revenue / Employee
323.85K AUD
Profits / Employee
-1.92M AUD
Market Cap
3.03B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 81 | 8 | 10.96% |
| Jun 30, 2024 | 73 | -10 | -12.05% |
| Jun 30, 2023 | 83 | 6 | 7.79% |
| Jun 30, 2022 | 77 | -6 | -7.23% |
| Jun 30, 2021 | 83 | -19 | -18.63% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mesoblast News
- 5 days ago - Mesoblast Financial Results and Corporate Update Webcast - GlobeNewsWire
- 13 days ago - Mesoblast Touts High Survival Rates For FDA-Approved Cell Therapy - Benzinga
- 13 days ago - Mesoblast Touts High Survival Rates For FDA-Approved Cell Therapy - Benzinga
- 14 days ago - High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD - GlobeNewsWire
- 14 days ago - Mesoblast: Real-World Data Validates The Bull Case For Ryoncil - Seeking Alpha
- 4 weeks ago - Ryoncil® Net Revenues Increase for the Quarter to US$30M - GlobeNewsWire
- 4 weeks ago - Mesoblast Says Most Children Survive After Early Use Of FDA-Approved Cell Therapy For Organ Transplant Related Complication - Benzinga
- 4 weeks ago - Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment - GlobeNewsWire